Imaging Cancer-associated Cachexia: Utilizing Clinical Imaging Modalities for Early Diagnosis.

Cancer-associated cachexia (CAC) is a prevalent condition that accelerates cancer progression and heightens treatment-related adverse effects in patients by affecting multiple organ systems. Despite the profound impact of CAC on clinical management and treatment outcomes of patients with cancer, the current understanding of mechanisms associated with the condition, as well as the tools necessary for early diagnosis, are limited. Currently, the clinical diagnosis of CAC relies on weight change-based assessments, which have limited sensitivity and cannot identify patients at risk for CAC.

Irisin reverses high-fat diet-induced metabolic dysfunction via activation of brown adipose tissue in mice.

Background: High-fat diet (HFD) induces negative effects on the activity of interscapular brown adipose tissue (iBAT) and systemic energy metabolism. Irisin, a small hormonal agent known to modulate metabolism has been used for intervening HFD-induced obesity. However, its mechanism of action on iBAT function remains to be fully elucidated.

A [F]FDG PET based nomogram to predict cancer-associated cachexia and survival outcome: A multi-center study.

Objectives: Cancer patients with cachexia face poor prognosis and shortened survival. Early diagnosis and accurate prognosis prediction remain challenging. This multi-center study aims to develop and externally validate a nomogram integrating [F]fluoro-2-deoxy-D-glucose ([F]FDG) PET findings and routine clinical biochemistry tests for predicting cancer-associated cachexia, while also assessing its potential prognostic value.